NTRK1 and central nervous system cancer: In particular, MEK1/2, BRAF, and TRK inhibitors have demonstrated significant promise in pediatric gliomas and extracranial solid tumors harboring these alterations and warrant further investigation in larger trials, as well as clinical consideration when these alterations are present.